hrp0094p1-169 | Growth B | ESPE2021

Safety of growth hormone and cardiovascular outcomes in patients with Noonan syndrome enrolled in NordiNet® International Outcome Study (IOS) and the ANSWER Program

Romano Alicia , Kaski Juan Pablo , Dahlgren Jovanna , Kelepouris Nicky , Pietropoli Alberto , Rohrer Tilman R. , Polak Michel ,

Introduction: Growth hormone (GH) treatment has been shown to increase height velocity and adult height in patients with Noonan syndrome (NS). NS is also associated with cardiovascular (CV) anomalies, namely pulmonary stenosis and hypertrophic cardiomyopathy. Concerns persist about the role of GH in progression of CV conditions despite data, albeit limited, showing low rates of CV events and left ventricular wall thickness remaining normal. This pooled analysi...

hrp0094p2-116 | Diabetes and insulin | ESPE2021

Sex differences over two decades for glycaemic control, pump use and insulin dose in patients aged 10-20 years with type 1 diabetes

Boettcher Claudia , Tittel Sascha R. , Meissner Thomas , Gohlke Bettina , Stachow Rainer , Dost Axel , Lanzinger Stefanie ,

Background: Therapy in type 1 diabetes has undergone a fundamental change over the last several decades, especially by the use of technical devices. Another change that took place is the growing awareness of sex differences of all kind, e.g. as influencing factors of metabolic control. Our study aimed to evaluate sex differences over two decades with regard to changes in glycaemic control, with regard to trends in insulin pump use and insulin dose. Migration b...

hrp0094p2-369 | Pituitary, neuroendocrinology and puberty | ESPE2021

6-Month GnRHa Formulations Are a Good Choice During the COVID-19 Pandemic and Beyond

R. Benson Matthew , N. Atkinson Stuart , M. Boldt-Houle Deborah , Miller Bradley S. ,

Introduction: Achieving/maintaining effective hormone suppression is fundamental in treating Central Precocious Puberty(CPP). CPP patients are vulnerable to late dosing as they cannot self-administer and require clinic/hospital visits for injections, currently exacerbated by COVID-19. In children, the hypothalamic-pituitary-gonadal axis may rebound faster than elderly oncology patients, so hormone escapes are possible with late dosing. Additionally, the stimul...

hrp0097fc7.5 | Sex differentiation, gonads and gynaecology or sex endocrinology | ESPE2023

SGPL1 deficiency, a cause of 46XY DSD and adrenal insufficiency, impairs lipid metabolism and steroidogenesis in Leydig cells

Kwong RMW , Smith CJ , Williams J , Hall C , Metherell LA , Prasad R

Loss of function mutations in SGPL1 (sphingosine-1-phosphate lyase) give rise to a multisystemic syndrome with predominating features of primary adrenal insufficiency (PAI) and steroid resistant nephrotic syndrome. Retrospective analysis of our patient cohort and the wider literature also demonstrated primary gonadal insufficiency in a third of male patients with microphallus and bilateral cryptorchidism (all with concomitant adrenal disease and high mortality in infa...

hrp0097fc13.3 | Pituitary, neuroendocrinology and puberty 2 | ESPE2023

Variants in Methyl-CpG-binding protein 2 (MECP2) are associated with X-Linked Central Precocious Puberty

E Read Jordan , Guasti Leonardo , Paganoni Alyssa , Korbonits Marta , R Howard Sasha

Whilst several key genetic contributors to the phenotype of central precocious puberty (CPP) have been recognized, many familial cases remain without clear a genetic aetiology. Causal genetic variants are reported in imprinted genes Makorin ring finger protein 3 (MKRN3) and Delta-like homolog 1 (DLK1), alongside Kisspeptin-1 (KISS1) and (KISSR1), implicating mis-regulation of transcriptional control of the kisspeptin and GnRH neuroendocrine systems in onset of CPP. We recently...

hrp0097t16 | Section | ESPE2023

Dose dependent risks of glucocorticoid treatment in classic CAH

Saragolou Kyriakie , Casteràs Anna , Will Charlton R , Barnes Chris , Thornton Paul

Introduction: In congenital adrenal hyperplasia (CAH), glucocorticoid (GC) treatment must perform two functions – to replace cortisol deficiency and to suppress the excess production of adrenal androgens. Unfortunately, androgen suppression usually requires supraphysiologic GC doses, which are associated with serious comorbidities. Our study examined the exposure or dose-dependent relationships between GCs and GC-related adverse events (GCRAEs) and comor...

hrp0097p1-232 | Diabetes and Insulin | ESPE2023

A Case with Alstrom Syndrome with a Novel Pathogenic Variant In ALMS1 gene as a Rare Cause of Diabetes Mellitus

Dağdeviren Çakır Aydilek , Gizem Bolaç Özyılmaz Leyla , Uçar Ahmet

Introduction: Alstrom syndrome (ALMS) is an autosomal recessive disorder characterized by multiple organ involvement, including progressive cone-rod dystrophy, sensorineural hearing loss, childhood obesity, and type 2 diabetes mellitus. Pathogenic variants in the ALMS1 gene are the known cause for the occurrence of this devastating condition. Here, we reported a case of Alstrom syndrome with a novel homozygous variant in the ALMS gene, who presented to our cli...

hrp0097p1-90 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Low-Dose Diazoxide Therapy in Hyperinsulinaemic Hypoglycaemia

Yi-Lin Ng Amy , Agarwal Pankaj , Vijayan Roopa , B Arya Ved , R Kapoor Ritika , Shah Pratik

Background: Diazoxide therapy is used as first line treatment in hyperinsulinaemic hypoglycaemia (HH). Apart from a single study reporting efficacy of low dose diazoxide in small for gestational age (SGA) infants, diazoxide has been reported to be used in doses of 5-20 mg/kg/day [1].Objective: To report the outcomes of infants with HH responsive to low dose diazoxide (≤5mg/kg/day).Method...

hrp0097p1-344 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Neurobehavioural impairments in children with septo-optic dysplasia spectrum conditions: A systematic review

Mann Amy , Aghababaie Arameh , Kalitsi Jennifer , Martins Daniel , Paloyelis Yannis , R Kapoor Ritika

Background: Septo-optic dysplasia (SOD) is a rare condition diagnosed in children with two or more of the following: hypopituitarism, midline brain abnormalities, and optic nerve hypoplasia (ONH). Children with SOD experience varied visual impairment and endocrine dysfunction. Autistic-like behaviours have been reported, however the nature and prevalence of these neurobehavioural impairments remain to be fully understood. The present systematic review aimed to...

hrp0097p1-193 | Thyroid | ESPE2023

Thyroid hormone resistance syndrome due to a new mutation in the TRHA gene

Tuhan Hale , Donbaloğlu Zeynep , Kırbıyık Özgür , Parlak Mesut , Demir Korcan

Introduction: Resistance to thyroid hormones is defined as lack of response of peripheral tissues to triiodothyronine (T3) which is the active form of thyroid hormones. In general (85%) a mutation is detected in the thyroid hormone receptor β (THRB) gene and more rarely, the thyroid hormone receptor α (TRHA) gene.Case: A 4.7-year-old boy, was admitted to the pediatric endocrinology outpatient clinic of Akdeniz...